Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

October 12, 2017: By Jon Swedien

1 Ophthalmic NewsAzura Ophthalmics has completed a $16 million Series B funding round that will enable it to further develop its dry eye disease treatment candidates, the Israeli company announced Oct. 10.

Azura is developing a portfolio of compounds in combination with a novel drug delivery platform designed to treat meibomian gland dysfunction (MGD), the leading cause of dry eye disease, the company said.

The firm also is preparing for a Phase IIa trial of a drug therapy that has shown efficacy in an initial clinical proof of concept study.

The round was led by a syndicate of OrbiMed, TPG Biotech, and Brandon Capital’s Medical Research Commercialisation Fund, with participation from an existing investor, Ganot Capital.

The company also announced Oct. 10 that Anat Naschitz of OrbiMed, Heather Preston of TPG Biotech, and Chris Nave of Brandon Capital will join the company’s board of directors.

The board also includes Guy Katsav of Ganot Capital, Azura CEO Marc Gleeson, and Yair Alster, MD, Azura’s founder and chief technology officer.

Alster previously co-founded several companies, including Forsight Vision 4 (sold to Roche-Genentech), Forsight Vision 5 (sold to Allergan), and Notal Vision, a commercial stage company.

Gleeson spent 14 years at Allergan as vice president of global marketing for ophthalmology, and then he joined Oculeve.

Azura has also named Charles Bosworth, formerly of Allergan, as its chief medical officer.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022